Cannabis Use Linked to Altered Functional Connectivity of the Visual Attentional Connectivity in Patients With Psychosis and Controls by Sami, Musa Basseer et al.
Page 1 of 11
Schizophrenia Bulletin Open
doi:10.1093/schizbullopen/sgaa018
© The Author(s) 2020. Published by Oxford University Press on behalf  of the University of Maryland's school of medicine, Maryland 
Psychiatric Research Center.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), 
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Cannabis Use Linked to Altered Functional Connectivity of the Visual Attentional 
Connectivity in Patients With Psychosis and Controls
Musa Basseer Sami*,1,4, , Robert A McCutcheon1, , Ulrich Ettinger2, Steve Williams3, Dave Lythgoe3, Philip McGuire1, 
and Sagnik Bhattacharyya1
1Institute of Psychiatry, Psychology and Neurosciences King’s College London, London, UK; 2University of Bonn, Bonn, Germany; 
3Centre for Neuroimaging Sciences, King’s College London, London, UK; 4Institute of Mental Health, University of Nottingham, 
Nottingham, UK
*To whom correspondence should be addressed; Institute of Mental Health, University of  Nottingham, Triumph Road, Jubilee Campus, NG7 
2TU UK; e-mail: musa.sami@nottingham.ac.uk
Background: Both chronic cannabis use and psychotic 
disorders are associated with abnormalities in visual atten-
tional processing. Using functional magnetic resonance im-
aging (fMRI), we sought to determine whether there would 
be a difference in functional connectivity in patients and 
controls with and without a history of cannabis use in the 
visual and dorsal attention networks.  Methods: Resting-
state fMRI data were acquired in patients with early psy-
chosis with (EPC  =  29) and without (EPNC  =  25); and 
controls with (HCC = 16) and without (HCNC = 22) can-
nabis use. Results: There was a patient effect in both Visual-
Dorsal Attention Internetwork (F(1,87) = 5.326, P = .023) 
and the Visual Network (F(1,87)  =  4.044, P  =  .047) 
and a cannabis effect in the Dorsal Attention Network 
(F(1,87) = 4.773, P = .032). These effects were specific to the 
networks examined with no evidence for significant patient 
or cannabis effects in other canonical networks. Patients 
with a history of cannabis use showed increased connec-
tivity in the Dorsal Attention Network (134%, P  =  .019) 
and Visual Dorsal Attention Internetwork (285%, P = .036) 
compared to non-using controls. In the EPC group con-
nectivity of the Visual Network (ρ = 0.379, P = .042) and 
Visual-Dorsal Attention Internetwork (ρ = 0.421, P = .023) 
correlated with visual hallucinations which were signifi-
cantly different from EPNC (P  =  .011). Dorsal attention 
network strength correlated with severity of dependence for 
cannabis (ρ = 0.215, P = .04). Conclusion: We demonstrate 
specific cannabis and patient effects in networks associated 
with visual attentional processing. There is a differential as-
sociation with hallucinatory symptoms in patients with and 
without a history of cannabis use. This may indicate that 
dysconnectivity in these networks serves different roles in the 
context of cannabis use.
Key words:  resting state/cannabis/psychosis/fMRI/dor
sal attention network/visual network
Introduction
Cannabis use and early psychosis are often comorbid 
with a large meta-analysis showing regular cannabis use 
in 30%–40% of cases at onset of psychosis and associ-
ated with poorer prognosis.1,2 However, the neurobiolog-
ical substrates underlying the association of psychotic 
disorders in patients who have used cannabis remain 
unclear. Both cannabis use and psychosis have been as-
sociated with perturbations in functional connectivity in 
line with the “dysconnectivity hypothesis”.3,4 However 
the nature of such dysconnectivity has not been clarified: 
in psychosis studies have shown hypoconnectivity,5–8 
hyperconnectivity9,10 and mixed patterns11–13; as 
is the case in cannabis use: (hypoconnectivity,14,15 
hyperconnectivity16–19). Reconciliation of connectivity 
findings in cannabis and psychosis would require study 
of both cannabis and psychosis groups together.
One line of investigation would be to look at network 
connectivity of visual attention processing as this is known 
to be altered in both cannabis use and psychotic disorders. 
There is evidence for several such abnormalities in psy-
chosis: impairment of smooth pursuit and antisaccades 
eye movements20–24 as well as abnormalities in motion, 
contrast detection, reading tasks and face perception.25–27 
Similarly in cannabis use impairment in contrast sensi-
tivity,28 attention to motion processing29 and visuo-spatial 
processing30,31 has been demonstrated.
Complementing this is evidence of aberrant functional 
connectivity in visual and attentional networks in both 
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psychosis and cannabis use. There is a body of evidence 
showing tasks to elicit abnormalities in visual attentional 
processing in psychosis,32–34 recent work has implicated 
abnormal visual network activation in schizophrenia35; 
and a history of cannabis use has been shown to be as-
sociated with visual and attentional reorganization36 and 
associated with greater connectivity between frontal cog-
nitive control regions and the dorsomedial visual area.37
Of note we have shown, in our current sample, 
alterations in smooth pursuit eye movements (SPEMs) in 
patients with early psychosis with and without a history 
of cannabis use.38 Patients without a history of cannabis 
use exhibited deficiency in peak gain not seen in patients 
with a history of cannabis use. Examination of functional 
connectivity of the brain networks which underpin visual 
and attentional processes may thus allow us to determine 
differences in dynamic functional interactions in patients 
with and without a history of cannabis use.
Therefore, drawing on the dysconnectivity hypoth-
esis, previous literature as well as our findings in SPEM 
described above, we hypothesized that there would be a 
perturbation in functional connectivity in patients with a 
history of cannabis use specifically in the visual and dorsal 
attention networks. We expected to see evidence for both 
a cannabis and psychosis effect on functional connectivity 
and the network which connects the two (the “visual-dorsal 
attention internetwork”). We also wished to identify spe-
cific dysconnectivity in the EPC group which may help in 
identifying targets for treatment in this poor-prognosis group.
Furthermore the dysconnectivity hypothesis suggests 
that visual abnormalities in schizophrenia have shared 
underpinnings with the false inference seen in the posi-
tive symptoms of psychosis.4 Both visual processing and 
our cognitive understanding about the external world 
rely on the integration of perceptual information in the 
brain with prior expectations and subsequent predic-
tion to create an external world which is perturbed in the 
presence of dysconnectivity. Although more intuitive for 
hallucinations a similar mechanism has been argued for 
delusions.4,39 To examine this we tested whether network 
strength in visual processing regions would correlate with 
the positive symptoms of psychosis, particularly in relation 
to hallucinatory symptoms. We also tested to see if func-
tional connectivity in these networks was associated with 
eye movements, general functioning and cannabis use.
Methods
Sample
The EfCiP (Effect of Cannabis in Early Psychosis; 
Stanmore Research Ethics Committee: 17/LO/0577) 
study was a cross-sectional study of individuals aged 
18–38 forming 4 groups: (1) patients with early psychosis 
(presentation to mental health services within 5 years of 
psychosis onset) with a history of cannabis use (EPC); 
(2) patients with early psychosis without a history of 
cannabis use (EPNC); (3) healthy controls with a history 
of cannabis use (HCC) and (4) healthy controls without 
such a history (HCNC). Diagnosis was confirmed using 
Structured Clinical Interview for DSM-IV for Axis 
I  disorders (SCID).40 For full details of recruitment 
see supplementary material. All “non-cannabis users” 
(EPNC, HCNC) reported use a few times a year, only 
once or twice or not at all; whereas all “cannabis users” 
(EPC, HCC) reported use at least a few times each month, 
more than weekly or daily (supplementary material).
Clinical and Biological Measures
On the study day, all participants underwent the 
Structured Clinical Interview for DSM-IV40 for diag-
nosis, Positive and Negative Syndrome Scale (PANSS)41 
to assess symptom scores and a standardized battery to 
assess symptoms, functioning and drug use. See supple-
mentary methods for further details.
In an exploratory fashion we devised a score to cap-
ture 5 features of use behavior associated with psychosis 
outcomes (heaviness, early first use, lifetime abuse, per-
sistence and potency) to give a cumulative score out of 10 
for each participant from the information collected in the 
above measures (named Cannabis Psychosis Score [CPS] 
for further discussion on how these use-behaviors relate 
to psychosis see supplementary material).
SPEM data were collected from participants using 
an eye movement battery developed for psychiatric and 
neurological disease (EyeLink 1000, SR Research Ltd.). 
SPEM mean velocity gain scores were calculated at 3 si-
nusoidal target frequencies (0.2, 0.4, and 0.6 Hz) (supple-
mentary material).
Image Acquisition and Analysis
T1 weighted images and 5-minute resting-state data were 
acquired on a 32 channel head coil (Nova Medical) on 
a General Electric 3-Tesla system. Preprocessing was 
undertaken using the CONN toolbox (version 18.b) 
for Statistical Parametric Mapping software (SPM 12 
(6906))42 running in Matlab R2018a (The Mathworks). 
Cortical parcellation was undertaken using the Gordon 
atlas, containing 333 cortical nodes.43 Full details for ac-
quisition, preprocessing and parcellation procedures are 
reported in the supplementary material.
Statistics
Demographic and clinical data were compared across 
groups using ANOVA tests for continuous measures and 
chi-squared tests for categorical data. Follow-up post hoc 
tests were conducted between groups, as appropriate. To 
compare clinical parameters between EPC and EPNC 
groups and cannabis use parameters between HCC groups 
we undertook 2-sided t-tests (preceded by Levene’s test for 
equality of variances) or chi-squared tests as appropriate. 
D
ow
nloaded from
 https://academ
ic.oup.com
/schizbullopen/article-abstract/1/1/sgaa018/5822619 by guest on 06 July 2020
Page 3 of 11
Cannabis Use Linked to Altered Functional Connectivity
Since data on “days since last joint” were notably skewed 
median and interquartile range (IQR) are reported for this 
variable and Mann Whitney U tests were used to test sta-
tistical significance between EPC and HCC. We further 
tested whether motion parameters differed between groups 
using ANOVA (mean motion, mean global signal change). 
Statistical significance was set at P = .05. Statistical analysis 
was undertaken in IBM SPSS Statistics version 25 (IBM). 
Network based statistical analysis is detailed below.
Network Analysis
Canonical Networks. For each participant, the average 
network strength was defined as the mean z-transformed 
Pearson’s correlation coefficient between all nodes in the 
network of interest (ie, mean edge strength). For each par-
ticipant we calculated average network strength for 3 prede-
fined networks43: dorsal attention network (32 × 32 nodes, 
496 edges), visual network (39 × 39 nodes, 741 edges), and 
the visual-dorsal network internetwork, ie, the connectivity 
between the 2 distinct networks (39 × 32 nodes, 1248 edges).
We then performed 2×2 MANCOVA with follow-up 
ANCOVA using network strength for the 3 canonical 
networks as the outcome of interest and cannabis use 
and psychosis as the predictor variables covarying for 
mean motion. In further models we added covariates 
into the ANCOVA models which we expected might 
have the potential to confound our findings (Fagerstrom 
and AUDIT scores to index tobacco and alcohol use re-
spectively). Post hoc, we tested differences between the 
mean functional connectivity for the 4 groups (EPC, 
EPNC, HCC, HCNC) corrected for motion and applied 
Bonferroni correction (ie, by multiplying P value by 6). 
Since the controls who did not use cannabis (HCNC) 
represent “normal” connectivity and deviation from this 
indicates abnormal connectivity (dysconnectivity) we re-
port the other groups standardized to the HCNC mean.
To test for specificity of our findings to our networks 
of interest we undertook similar ANCOVAs for all other 
Networks parcellated by the Gordon Atlas and report 
these in the supplementary data.
Network Based Statistic. To further determine if  there 
was a specific subnetwork within the Dorsal Attention 
Network and Visual Network differing between groups 
(EPC, EPNC, HCC, HCNC) we used the Network Based 
Statistic (NBS)8 (see supplementary methods for a full de-
scription). To determine the direction of group differences 
we extracted the network strength of this network and 
adjusted for mean motion, and subsequently covarying 
for Fagerstrom, AUDIT scores. To determine the op-
timal primary threshold NBS was performed across 100 
thresholds ranging from F = 2.00 to F = 4.00.
Network visualization was undertaken with BrainNet 
Viewer 1.63 (https://www.nitrc.org/projects/bnv/).44
In exploratory analyses, we tested for correlations between 
network strength and symptoms using 2-tailed Spearman’s 
ρ. We examined these correlations separately in each pa-
tient group (EPC, EPNC). To distinguish between state 
and trait measures we used PANSS positive scores (total 
PANSS positive score and P3: Hallucinatory experiences) 
for state measures, and presence of positive symptoms from 
Module B of the SCID (visual hallucinations) for a trait 
measure (ie, if the symptom had ever been experienced). In 
networks where a significant correlation was found in one 
group we tested to see if this was significantly different from 
the correlation coefficient in the other group using 2-tailed 
Fisher r-to-z transformation. For completeness the correla-
tion of all positive PANSS/SCID measures with Network 
Connectivity are reported in the supplementary material. 
We also tested correlations between network strength and 
GAF, chlorpromazine equivalents, mean SPEM velocity 
gain and cannabis use measures.
Finally as a supplementary analysis we tested to see if  
connectivity was related to patient status (schizophrenia 
spectrum diagnosis or not; affective disorder diagnosis or 
not; and currently on/off antipsychotic medication). Since 
these parameters were the same across both patient groups 
(EPC, EPNC see Results), this is not relevant to our main 
analysis and is reported in the supplementary material.
Results
A total of 103 participants were recruited into the study. 
One HCC was excluded due to cannabis intoxication, 
one HCNC was excluded due to a prolactinoma. Six 
participants (3 EPC, 3 EPNC) were not able to have mag-
netic resonance imaging (MRI) due to contraindications 
to MRI scanning. Two participants (EPNC) experienced 
claustrophobia and were unable to have an MRI scan and 
one self-terminated the scanning session before resting-
state acquisition. Hence, MRI and resting-state data were 
available for 92 participants: EPC: n = 29, EPNC: n = 25; 
HCC: n = 16; HCNC: n = 22.
One patient under an Early Intervention in Psychosis 
team had a first psychotic episode aged 12, 20 years be-
fore inclusion into the study, and had been asymptomatic 
off-treatment until re-presenting in their 30 seconds. One 
HCC suffered from Generalized Anxiety Disorder on 
no treatment and one HCC had Obsessive Compulsive 
Disorder 8  years prior to the study and was currently 
in remission maintained on low dose sertraline (50 mg). 
Exclusion of these cases in sensitivity analysis had no ef-
fect on the main results.
Demographics and Clinical Measures
Demographic and clinical measures by group are shown in 
table 1. As expected, patients had increased PANSS scores 
and decreased GAF compared to controls. Controls had 
higher IQ score compared to patients. Cannabis using 
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patients had increased Fagerstrom and AUDIT scores 
indicating increased tobacco and alcohol use compared 
to EPNC. There was no significant difference between 
EPC and EPNC in all clinical parameters: total PANSS 
and all subscales, chlorpromazine equivalents, age at di-
agnosis and duration since diagnosis, days spent in hos-
pital, proportion with schizophrenia spectrum disorder or 
affective diagnosis, GAF scores and Global Functioning 
and Social Functioning subscales (all P > .34).
The cannabis using groups had a history of heavy 
cannabis use with no significant difference in cannabis 
use parameters: age of first use (EPC: x̅  =  16.07  years 
[SD 2.51]; HCC: x̅  =  16.00 [SD 2.50]); hours subjec-
tively “stoned” in a day (EPC: x̅  =  5.55 [SD 5.01]; 
HCC: x̅ = 5.77 [SD 4.41]); days to smoke an eighth of 
an ounce of cannabis (EPC: x̅ = 9.56 [SD 11.36]; HCC: 
x̅ = 7.96 [SD 9.28]) and number of joints in a day (EPC: 
x̅  =  2.76 [SD 1.28]; HCC: x̅  =  2.95 [SD 2.21]) (all P > 
Table 1. Data Presented in Cells are Proportions for Discrete Data; Means (SDs) for Continuous Data
EPC EPNC HCC HCNC P-Value
n 29 25 16 22  
Sex 23/29 (79%) 16/25 (64%) 10/16 (63%) 11/22 (50%) All groups: .183
Age 25.57 (3.89) 26.29 (4.74) 27.11 (5.95) 28.16 (5.29) All groups: .416
Age at first presentation 23.39 (4.06) 23.29 (5.59) - - EPC vs EPNC: .937
AUDIT 8.79 (5.30) 3.40 (4.92) 7.75 (6.43) 3.59 (2.99) All groups: <.001  
EPC vs EPNC: .001  
EPC vs HCNC: .002
Fagerstrom 2.59 (1.74) 0.64 (1.75) 0.75 (1.74) 0 (1.74) All groups: <.001  
EPC vs EPNC: .001  
EPC vs HCC: .006  
EPC vs HCNC: <.001
Diagnosis   - - EPC vs EPNC: .476
 Bipolar affective 2 (6.9) 2 (8)
 Brief  psychotic 1 (3.4) 2 (8)
 Psychotic depression 1 (3.4) 0
 Psychosis NOS 0 2 (8)
 Schizoaffective 8 (27.6) 6 (24)
 Schizophrenia 11 (37.9) 11 (44)
 Schizophreniform 3 (10.3) 2 (8)
 Substance induced 3 (10.3) 0
Proportion SSD diagnosis 22/29 (76%) 19/25 (77%) - - EPC vs EPNC: .991
Proportion affective diagnosis 11/29 (38%) 8/25 (32%) - - EPC vs EPNC: .649
PANSS 53.24 (18.49) 53.36 (17.78) 34.56 (5.38) 31.05 (2.13) All groups: <.001  
EPC vs HCC: <.001  
EPC vs HCNC: <.001  
EPNC vs HCC: <.001  
EPNC vs HCNC: <.001
PANSS Hallucinations     EPC vs HCC: <.001  
EPC vs HCNC: <.001  
EPNC vs HCC: <.001  
EPNC vs HCNC: <.001
Proportion visual hallucinations 
history
15/29 (52%) 11/25 (44%)   EPC vs EPNC: .571
GAF 70.24 (8.98) 72.96 (11.40) 89.25 (4.93) 93.32 (2.13) All groups: <.001  
EPC vs HCC: <.001  
EPC vs HCNC: <.001  
EPNC vs HCC: <.001  
EPNC vs HCNC: <.001
CPZ equivalents 189.57 (174.15) 184.86 (176.05) - - EPC vs EPNC: .922
Proportion medicated 19/29 (66%) 17/25 (68%) - - EPC vs EPNC: .847
Intelligence Quotient 100.46 (12.73) 100.21 (14.38) 110.28 (6.93) 110.23 (7.98) All groups: .003  
EPC vs HCC: .053  
EPC vs HCNC: .042  
EPNC vs HCC .053  
EPNC vs HCNC: .043
Note: P-values are reported for omnibus tests (chi-squared, ANOVA) for all groups: group-wise comparisons reported as appropriate for 
post hoc tests (chi-squared, post hoc tests Bonferroni correction). Only significant post hoc tests shown. EPC, Early Psychosis with Can-
nabis use; EPNC, Early Psychosis without Cannabis use; HCC, Healthy Controls with Cannabis Use; HCNC, Healthy Controls without 
Cannabis Use; n, number of participants; SSD, Schizophrenia Spectrum Disorder; CPZ, Chlorpromazine.
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.65). There was a wide variability in days since last joint 
(EPC: median  =  65 [IQR: 1–530]; HCC: median  =  7 
[IQR: 1–1402]) the difference between groups was not 
significant (P =  .637). In the EPC group 12/29 (41.4%) 
tested positive for THC compared to 7/16 of the HCC 
groups (43.8%) (P = .877). There were significantly more 
individuals with SCID diagnosis of lifetime cannabis use 
disorder in the EPC group: 23/29 (79.3%) than the HCC 
group: 8/16 (50%) (P = .04), this was expected due to the 
psychosis comorbidity.
There were no differences in motion parameters be-
tween groups (supplementary table 1).
Canonical Dorsal Attention and Visual Networks
In dorsal attention and visual networks MANCOVA of 
all 3 network strengths across groups with mean motion 
as a covariate revealed trend-level patient and cannabis 
effects (patient: F(3,85)  =  2.584, P  =  0.059) (cannabis: 
F(3,85)  =  2.446, P  =  0.069) but no cannabis × patient 
interaction effect F(3,85) = 0.633, P = 0.595). Follow-up 
ANCOVA of the specific networks revealed (1) sig-
nificant patient effects in the Visual-Dorsal Attention 
Internetwork (F(1,87) = 5.326, P = 0.023); Visual Network 
(F(1,87) = 4.044, P = .047); and a trend-level effects in the 
Dorsal Attention Network (F(1,87) = 3.402, P =  .069); 
and (2) a cannabis effect in the Dorsal Attention Network 
(F(1,87)  =  4.773, P  =  .032) but not Visual (P > .5) or 
Visual-Dorsal Attention Network (P = .16). Of note these 
findings were specific to the Visual and Dorsal Attention 
Networks with no other patient or cannabis group effect 
for any of the other canonical networks (P ≥ .239 see 
supplementary material). Results remained significant 
for the patient effect after addition of AUDIT but not 
Fagerstrom score in the visual networks (P =  .045) and 
visual-dorsal internetwork (P = .025). For cannabis effect 
there was no group effect after addition of Fagerstrom 
and AUDIT scores as covariates.
Post hoc tests to test group differences showed the 
EPC groups to have highest connectivity compared to 
healthy controls in the Dorsal Attention Network (EPC 
mean connectivity strength 134% of HCNC, 95% CI 
119%–149%, P =  .019, Bonferroni corrected) and Visual 
Dorsal Attention Internetwork (EPC mean connectivity 
strength 285% of HCNC, 95% CI 196%–369%, P = .036, 
Bonferroni corrected). Group differences can be seen in 
figure 1. This difference remained significant after addition 
of Fagerstrom and AUDIT scores in the Visual Dorsal 
Attention Internetwork (EPC mean connectivity strength 
339% of HCNC, 95% CI 230%–507%, P = .045, Bonferroni 
corrected) but not in the Dorsal Attention Network.
There were no patient or cannabis effects for all other 
Canonical Networks parcellated by the Gordon Atlas 
indicating specificity of our findings to our networks of 
interest (supplementary material).
Network Based Statistic Defined Network
Significant networks were identified across a range of F 
thresholds (supplementary material). The most stringent 
F-Statistic threshold was extracted for further analysis. 
This network involved almost all nodes of the networks 
Fig. 1. Visual and dorsal attention network strength by group. EPC, Patients with history of cannabis use; EPNC, Patients without 
history of cannabis use; HCC, Controls with history of cannabis use; HCNC, Controls without history of cannabis use; *Statistically 
Significant (P value < .05; Error bars 95% CIs). Y-axis represents network strength means co-varied for mean motion.
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(64/71, 90.1% of all nodes) and 151 edges (151/4970, 
3.1% of all possible edges) (figure  2). The direction of 
connectivity strengths of the NBS defined network was: 
EPC>EPNC>HCC>HCNC (figure 1). Group differences 
in network strength remained significant after adjustment 
for AUDIT and Fagerstrom scores (P ≤ .014).
Correlation of Network Strength With Symptoms
Trait Measures. In the EPC group a history of visual 
hallucinations positively correlated with network strength in 
the following networks: visual network (ρ = 0.379, P = .042), 
visual-dorsal attention internetwork (ρ = 0.421, P =  .023) 
and NBS defined network (ρ = 0.487, P = .007). No such 
correlation existed in the EPNC group. The difference in 
correlations for EPC and EPNC were statistically signifi-
cant (visual network (P = .011); visual-dorsal internetwork 
(P = .011) and NBS defined network (P = .014)).
State Measures. In the EPNC group PANSS rated hal-
lucinatory behavior inversely correlated with network 
strength in the visual network (ρ  =  −0.499, P  =  .011) 
whereas no such correlation was evident in the EPC 
group. The difference in correlations for EPC and EPNC 
was statistically significant (P  =  .0031). In the EPNC 
group the visual network (ρ = −0.589, P = .002), dorsal 
attention network (ρ = −0.416, P =  .038) and NBS de-
fined network (ρ = −0.499, P = .011) inversely correlated 
with PANSS positive scores whereas no such correlation 
was evident in the EPC group (figure 3). The difference in 
correlations for EPC and EPNC were statistically signif-
icant: for the visual network (P = .007) and NBS defined 
network (P = .05).
Cannabis Use. Dorsal Attention Network strength 
positively correlated with Severity of Dependence Scale 
for cannabis use (ρ  =  0.215, P  =  .04) and for the CPS 
score (ρ = 0.281, P = .007). The CPS score further pos-
itively correlated with internetwork strength (ρ = 0.266, 
P = .011), and NBS defined network strength (ρ = 0.350, 
P < .001). To ensure this association was not accounted 
for by group difference between users and non users we 
further tested correlation restricted to the cannabis using 
groups (EPC and HCC). CPS score was associated with 
Dorsal Attention Network strength (ρ = 0.424, P = .004), 
internetwork strength (ρ = 0.369, P = .014) and NBS de-
fined network strength (ρ = 0.298, P = .05) (figure 4).
Other Clinical Parameters. There was no correlation for 
network strength for all canonical networks or for the 
NBS network with chlorpromazine equivalents or Global 
Assessment of Functioning. Fagerstrom and AUDIT 
scores did not correlate with any network strength (P > .1).
Eye Movements. There was no significant correlation for 
any network with SPEM velocity gain.
Discussion
We set out to test differences in visual network and 
dorsal attention network connectivity between patients 
and controls with and without a history of  cannabis 
use. We show: (1) a patient effect on the visual and 
visual-dorsal attention internetwork networks such that 
patients have hyperconnectivity compared to controls; 
(2) a cannabis effect on the dorsal attention network 
such that cannabis users have hyperconnectivity in this 
Fig. 2. 
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Fig. 3. Network strength—PANSS symptom correlation by patient group. EPC, Patients with history of cannabis use; EPNC, Patients 
without history of cannabis use. Error bars represent 95% Confidence Intervals.
Fig. 4. Network strength—Cannabis Psychosis Score correlation in cannabis users. DAN, Dorsal Attention Network; VN, Visual 
Network; Inter, Visual-Dorsal Internetwork; NBS, Network Based Statistic defined Network; Error bars represent 95% Confidence 
Intervals.
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network compared to controls; and (3) specific evi-
dence for hyperconnectivity in the EPC group in the 
dorsal attention network and visual-dorsal attention 
internetwork. In exploratory analysis we further dem-
onstrate differential association in patient groups with 
symptomatology in the visually network and related 
networks and demonstrate association of  parameters 
of  cannabis use intensity with the dorsal attention net-
work and related networks. Using the Network Based 
Statistic we further characterize a sparser subnetwork 
which demonstrates strengthened differences between 
groups whilst showing a similar association with 
symptoms and cannabis use.
To our knowledge, this is the first study to examine 
the visual processing and related attention networks 
in patients with and without a history of cannabis use. 
There is an extensive literature on visual processing 
deficits in psychotic disorders25,45 including abnormalities 
of motion contrast perception and contour detection 
and their neural correlates46–49 alongside oculomotor 
abnormalities.21–24,50 Functional MRI studies have shown 
abnormalities in visual and attentional areas: a visual 
backward masking paradigm there was reduced cou-
pling between lateral occipital area and the superior 
frontal gyrus in patients with schizophrenia51; in a visual 
oddball task demonstrated disrupted connectivity be-
tween the interparietal sulcus and insula in patients with 
schizophrenia.32
Similarly, chronic cannabis use (independent of psy-
chosis) has been shown to be associated with deficits 
in depth of visual processing in the perception of am-
biguous visual stimuli52 and associated with reorganiza-
tion of visual and attentional areas.36,53 One study has 
examined functional connectivity in the frontoparietal 
network in patients, siblings and controls, finding no sig-
nificant interaction of cannabis use by group. However 
this may be limited due to dichotomizing cannabis into 
ever and never use.54 In contrast we recruited specifically 
for a history of heavy use and did not include experi-
mental or trivial use amongst users.
Our work extends the current body of evidence to 
show that there is both a patient and cannabis effect in 
key networks involved in visual attention processing and 
that the association of connectivity in these networks is 
different in cannabis and non-cannabis using patients. 
Functional connectivity across a range of networks 
in the EPC group is associated with a history of visual 
hallucinations—putatively implicating these networks 
as markers of pathogenicity. Conversely in the EPNC 
group increased network strength in visual network and 
dorsal attention networks is significantly associated with 
reduced positive symptoms state measures. This may in-
dicate an adaptive or protective response to psychosis 
in EPNC.
As a caveat to these inferences in a cross-sectional 
study we cannot definitively say that these findings 
represent pathogenicity or epiphenomena or a com-
pensatory response. Further longitudinal work in 
chronic use and psychosis and experimental manipula-
tion of  these networks, for example through acute can-
nabinoid challenges or using Transcranial Magnetic 
Stimulation (rTMS) and transcranial Direct Current 
Stimulation (tCDS) may help elucidate this relation-
ship more precisely. Δ-9-THC has been shown to dis-
rupt hyperconnectivity of  the brain reward circuit 
after a single dose in cannabis users55 whereas Default 
Mode Network hyperconnectivity in chronic users with 
psychosis is decreased after a single joint.56 From the 
findings in our study the Dorsal Attention Network 
may be a key network to target given the association be-
tween this network and its corrolaries with markers of 
cannabis use.
We did not, however, find an association between 
SPEM parameters and network strength indicating that 
these findings may be independent of  group differences 
we previously found in smooth pursuit performance in 
this sample.38 One possible reason for this is that the 
SPEM findings may index a lesion in non cortical sub-
strate such as subcortical, cerebellar and brainstem 
regions in eye movement processing which were not 
considered in this study. Alternatively the abnormality, 
if  subsisting in cortical regions may be driven by sparse 
neural populations which may be beneath the limit of 
detection of  the BOLD response. The optimal study de-
sign to investigate this difference, if  detectable in fMRI, 
may be administration of  a task based eye movement 
paradigm within the scanner.
We believe this study has several strengths. We de-
rive networks using canonical networks in a well es-
tablished parcellation43 as well as a network derived 
from the data (NBS). We use optimized procedures for 
stringent mean motion correction. Finally the patient 
groups (EPC and EPNC) were well matched across 
clinical parameters, indicating that differences were 
not due to a difference in illness severity, function, 
medication or diagnosis.
There are limitations to this study. Firstly, resting-
state scans were 5 minutes which are brief  but scans 
of  this duration have been shown to reliably identify 
anatomic brain networks.57,58 Secondly since we allowed 
trivial cannabis use in the non-cannabis use group it 
is conceivable that cannabis effects could have been 
modulating brain activity in non-using groups. However 
there is of  a clear demarcation between the groups in 
terms of  cannabis use and the nonuse cannabis groups 
had clear evidence for trivial usage (supplementary 
material). Of  note the Dorsal Attention Network 
hyperconnectivity was positively correlated with can-
nabis measures when examined across the entire sample. 
Thirdly, this study cannot fully disentangle the effect 
of  cannabis from nicotine use in the dorsal attention 
network. Combined cannabis and nicotine users have 
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been shown to have an association with increased cor-
tical connectivity across a range of  networks compared 
to either nicotine and cannabis users alone.59 However, 
in no network did Fagerstrom’s or AUDIT score corre-
late with connectivity. Our results also retain an ecolog-
ical validity in a real-world sample. Another limitation 
is that patients we recruited were in the mild-moderate 
range for symptoms and functioning this may not be 
representative of  severe patients where different brain 
adaptive changes may take place. This was to some 
extent unavoidable because patients engaged in a full 
study day and were recruited from a wide geographical 
area. Arguably the geographical representation makes 
the study more representative than a single site study. 
In supplementary analysis we did not find differences in 
patient status in connectivity (supplementary material) 
but it would be ideal to further examine these findings 
in a longitudinal study to determine both the effect of 
cannabis and medication use. Finally, for the purpose of 
the exploratory analysis, the Cannabis Psychosis Score 
is at this stage a provisional score. It has face validity 
and neurobiological findings we report are in line with 
the Severity of  Dependence scale. For full validation 
such a score should be validated in prospective epide-
miological studies and may be a future tool of  interest 
for further research (supplementary material).
Taken together, we demonstrate both cannabis and 
patient effects in visual attentional networks and a pat-
tern of hyperconnectivity in the EPC group. We show 
there is a distinct pattern of association between network 
strength and hallucinatory symptoms between patients 
who use and do not use cannabis. This may indicate that 
dysconnectivity in these networks serves different roles in 
the context of cannabis use.
Supplementary Material
Supplementary data are available at Schizophrenia 
Bulletin Open online.
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